Following the likes of Eli Lilly and Sanofi into the smart insulin field, Novo Nordisk has acquired UK group Ziylo and its glucose binding molecule platform to create glucose responsive insulins in a deal potentially worth US$800 M. These next-generation insulins would help eliminate the risk of hypoglycaemia and allow for a safer and more effective insulin therapy. Prior to closing of the acquisition, Ziylo spun out certain research activities to new company Carbometrics, which has then entered into a research collaboration with Novo.